The aim of this study was to determine the efficacy of palonosetron combined with dexamethasone in prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) in patients receiving high-dose (HD)-CT with auto-SCT, and the efficacy of a second dose of palonosetron in treating breakthrough emesis. One hundred thirty-four patients treated with HD-CT and auto-SCT for hematologic malignancies received palonosetron as prophylaxis for CINV on the first day of conditioning; patients were also administered dexamethasone throughout the entire period of conditioning. If breakthrough emesis occurred, a second dose of palonosetron was administered at 72 h after the first administration. Complete response and complete protection were observed in 36 and 26% of patients, respectively. One-half of the patients, re-treated with palonosetron for breakthrough emesis, were successfully rescued. Treatment with palonosetron plus dexamethasone seems to be encouraging in terms of prophylaxis of CINV and treatment of breakthrough emesis in the setting of HD-CT.
Introduction
The intensity, onset and duration of chemotherapy (CT)-induced nausea and vomiting (CINV) depend on the emetogenic potential and dose of therapeutic agents, 1 as well as on individual patient characteristics. 2 CINV is reported by patients to have substantial negative effect on the quality of life. 3 In addition, uncontrolled CINV can lead to severe clinical conditions, such as electrolyte imbalance, dehydration and malnutrition, and thus uncontrolled CINV not only compromises quality of life, but also influences the patient's ability to respond to treatment. 4 In the 1990s, the introduction of serotonin receptor antagonists (5-HT 3 RAs) improved the management of acute CINV associated with both moderately and highly emetogenic CT, [5] [6] [7] [8] but no improvement was shown in the prophylaxis of delayed CINV. [9] [10] [11] [12] The second-generation 5-HT 3 RA, namely palonosetron, and the neurokinin receptor antagonist, aprepitant, have improved not only the prevention of acute CINV, but also the prophylaxis of delayed CINV [13] [14] [15] [16] [17] [18] [19] after both moderately and highly emetogenic CT. However, control of delayed CINV is still an open problem, especially in patients undergoing multiple-day [20] [21] [22] [23] or high-dose (HD)-CT. [24] [25] [26] [27] Two recent studies 28, 29 have shown the efficacy and safety of palonosetron plus dexamethasone in preventing CINV during and after multiple-day CT.
Palonosetron is a second-generation 5-HT 3 RA with unique pharmacological and pharmacodynamic properties, which include a half-life that is significantly longer than that of first-generation 5-HT 3 RAs (about 40 vs 4-8 h, respectively), and a relatively high binding affinity for the 5-HT 3 receptor. 30 Starting from our experience with palonosetron plus dexamethasone in multiple-day CT, 29 the present study evaluated the efficacy, in terms of complete response (no emesis, no rescue therapy), of a single dose of palonosetron administered on the first day of a conditioning regimen together with dexamethasone administered throughout the entire period of conditioning in hematological patients receiving HD-CT and auto-SCT.
Patients and methods
One hundred thirty-four patients undergoing auto-SCT for hematologic malignancies were consecutively included in the study. All patients gave written informed consent for participation. In all, 80 (60%) patients were male and 54 (40%) were female. The median age was 53 years (range, . The most frequent diagnoses were multiple myeloma (MM) (52 (39%) patients) and non-Hodgkin's lymphoma (NHL) (50 (37%) patients); 13 (10%) patients had Hodgkin's disease and 19 (14%) were diagnosed with AML.
On the first day of the conditioning regimen, patients received a single dose of palonosetron (0.25 mg i.v.) and dexamethasone (8 mg i.v.) 30 min before starting CT. An additional dose of dexamethasone (4 mg twice daily i.v.) was administered every other day during the conditioning regimen. If breakthrough emesis occurred, a second dose of palonosetron (0.25 mg i.v.) was administered, but only at 72 h after the first administration. The occurrence of breakthrough emesis before 72 h was considered as treatment failure, and patients could receive any antiemetic drug.
The primary end point of the study was evaluation of the efficacy of palonosetron in terms of complete response (no emesis, no rescue therapy) during the conditioning regimen and within 5 days after the end of the conditioning regimen. Secondary end points were the evaluation of complete protection (no emesis, no significant nausea, no rescue therapy), the incidence of nausea and vomiting of any grade, and the efficacy of a second dose of palonosetron in treating breakthrough emesis. The safety of palonosetron was also evaluated. The number of vomiting episodes, grade of nausea and need for rescue therapy were recorded in patient diaries according to our standard policy for data management. Table 1 ). Complete response was reported in 48 (36%) patients, and among these, 35 (26%) patients had complete protection from CINV. In all, 27 (20%) and 17 (13%) patients experienced mild nausea and only one episode of vomiting (CINV grade 1), respectively (Tables 2 and 3 ). More-than-mild nausea or more than a single episode of vomiting (CINV grade 2-3) was observed in 72 (54%) and 69 (51%) patients, respectively (Table 3) . No patient experienced grade 4 vomiting.
Results

Patients
Considering the individual conditioning regimens, complete response and complete protection were observed in 74 and 53%, 58 and 42%, 38 and 24%, and 24 and 18% of patients treated with idarubicin plus dexamethasone, melphalan 140 mg/m (Table 4) . Breakthrough emesis occurred in 86 (64%) patients. Thirty-five patients (26%) experienced breakthrough emesis within 72 h after the first dose of palonosetron, but were considered as having violated the study protocol. In 28 patients, vomiting episodes occurred 48 h after the first dose of palonosetron. The 51 (38%) patients who experienced breakthrough emesis 72 h after the first dose of palonosetron were retreated with palonosetron as rescue therapy, and 25 (50%) were successfully rescued (Table 5) . It is worth noting that among the patients who violated the study protocol, nine out of 20 (45%) patients re-treated with palonosetron for the onset of breakthrough emesis 48 h after the first dose were rescued. Mild and transient headache related to palonosetron treatment was observed in 13 (10%) patients.
Discussion
Nausea and vomiting are still an open problem in HD-CT. On conditioning with 4 1 day of CT, patients are at risk for CINV throughout the entire treatment period. Moreover, daily and continuous emetogenic stimulus prevents clear differentiation between acute and delayed CINV, and the two phases often overlap, 31 rendering antiemetic prophylaxis problematic. The guidelines for CINV provided by ASCO and MASCC recommend prophylaxis with first-generation 5-HT 3 RAs, 32, 33 considering that the efficacy of first-generation 5-HT 3 RAs alone ranges from 5 to 15% (complete response), 24, 25 and increases to 20-50% with the addition of dexamethasone. 26, 27 Although the use of palonosetron has been proposed in HD-CT as for multiple-day CT, 31 specific dosing-schedule studies are still not well defined. In a recent study on patients undergoing 5 consecutive days of dexamethasonebased CT for germ-cell cancer, Einhorn et al. 28 administered palonosetron before CT and on days 3 and 5 in combination with dexamethasone. This combination was highly effective in controlling both vomiting and nausea. In this study, the majority of patients reported the absence of emesis on days 1-5 (51%) and on subsequent days 6-9 (83%), which was associated with a high degree of nausea control (72% on days 1-4 and 85% on days 5-9). The most common treatment-related adverse events were headache (17.1%) and constipation (9.8%). No changes in electrocardiogram (ECG) intervals or cardiac rhythm were observed after either single or multiple administrations of palonosetron.
In the setting of multiple-day CT, the results of our earlier experience with palonosetron in patients with hematologic malignancies was encouraging in terms of complete protection from CINV (80%). 29 Moreover, we planned a prophylaxis regimen with short and low-dose dexamethasone and only one administration of palonosetron, with a second administration reserved only for breakthrough emesis treatment, which rescued 67% of the patients. The only treatment-related adverse events associated were transient constipation or mild and transient headache.
Starting from this positive experience, we adopted the same palonosetron CINV prophylaxis protocol for patients undergoing HD-CT and auto-SCT. We maintained the same dose of palonosetron to reduce the risk of extrahematologic toxicity. Likewise, the dose of dexamethasone was not changed, in order to minimize the risk of excessive immunosuppression. The incidence of the overall complete response (36%) and complete protection (26%) was lower than that observed in the multiple-day CT setting, although palonosetron had a similar efficacy (50%) in rescuing patients with breakthrough emesis. Moreover, the subgroup analysis showed differences in efficacy among the different conditioning regimens.
In auto-SCT, several factors may contribute to the onset of nausea and vomiting, including type of conditioning regimen and use of antibiotics or analgesics, as well as concomitant mucositis. Moreover, in auto-SCT, no patient is CT naive. This fact could partially explain the reduced efficacy of antiemetic prophylaxis in the HD-CT setting.
Lopez-Jimenez et al. evaluated the incidence and severity of CINV in a similar number of transplant patients (n ¼ 100). 34 All patients received 5-HT3 RA as CINV prophylaxis (ondansetron in 95.8% of cases). Despite CINV prevention, complete response occurred only in 20% of transplant patients and antiemetic rescue therapy was ineffective.
The clinically relevant efficacy of palonosetron in rescuing patients with breakthrough emesis may be explained by its differentiating pharmacological profile compared with first-generation 5-HT 3 RAs. Our data indicate that palonosetron shows long-lasting activity that may be related to its longer half-life and its unique interaction with the 5-HT 3 receptor. 35 In fact, palonosetron seems to show positive cooperativity with the 5-HT 3 receptor, and thus the binding affinity increases, as additional palonosetron molecules become bound to the receptor. This characteristic, which is not shared by firstgeneration 5-HT 3 RAs, may partly account for the effective clinical control of CINV observed with palonosetron. Moreover, the successful rescue of 45% of the 20 patients re-treated with palonosetron 48 h after the first dose suggests that it may be possible to anticipate a second dose if breakthrough emesis occurs.
Further efforts should be directed towards the design of an effective antiemetic regimen in patients receiving HD-CT and auto-SCT. On the basis of our experience, clinical trials of antiemetic therapy in this setting should evaluate the best combination therapy, which should always include palonosetron.
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